International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

In Silico Clinical Trials - Review

Dr. Samuel Santhosh[1], Dr. R Divya[2]

Saveetha Medical College & Hospital, Chennai, Tamil Nadu, India

Abstract: ***In silico clinical trials (ISCTs) represent a game - changing advancement in medical research and have the potential to revolutionize the development and evaluation of therapies. By utilizing computational models and simulations, ISCTs offer a cost - effective and time - efficient alternative to traditional clinical trials. They provide a virtual testing ground to assess the safety, efficacy and dosage optimization of interventions, while minimizing ethical concerns associated with human trials. The versatility of ISCTs spans across various medical fields, enabling researchers to explore personalized medicine approaches and refine treatment strategies. Although challenges remain in accurately representing human physiology within computational models, ongoing advancements in data integration and validation techniques are rapidly improving the reliability and predictive capabilities of ISCTs. Overall, in silico clinical trials hold immense promise for accelerating therapeutic development, enhancing patient care and driving the future of medical research. This review article provides an in - depth overview of various ISCTs types, its advantages, limitations and their applications in drug development from the existing literatures.***

Keywords: In silico clinical trials**,** Pharmacokinetic modeling, pharmacodynamic modeling, Virtual patient populations, Machine learning, artificial intelligence, Model - based drug development

1. Introduction

Drug development is an expensive and complex process that involves several stages, including preclinical studies, clinical trials and regulatory approval. Clinical trials are a critical step in drug development, as they are used to evaluate the safety and efficacy of new drugs in human subjects. They have been the mainstay for a drug to be discovered, tested on animals and humans before they can be brought into the market for the benefit of the general public. They have paved way for the availability of the plethora of the lifesaving and morbidity mitigating medications that the physician can choose from now. However, traditional clinical trials are expensive, time - consuming and have a high failure rate (1).

In silico clinical trials (ISCTs) have emerged as a promising approach to reduce the cost and time of clinical trials by simulating the effects of drugs in virtual patients. Even though ISCTs were being conducted prior to the year 2020, the COVID 19 pandemic and a fear of a repeat pandemic has given an accelerated boost for the ISCTs to be accepted and adopted more. This review article provides an in - depth overview of ISCTs and their applications in drug development (2).

In silico clinical trials (ISCTs) are a relatively new approach to drug development that involve the use of computer models and simulations to simulate the effects of drugs on virtual patients. The term "in silico" refers to the use of computer simulations to study biological systems, as opposed to "in vivo" (in living organisms) or "in vitro" (in a test tube). ISCTs have emerged as a promising approach to reduce the cost and time of clinical trials, while also improving the accuracy and efficiency of drug development (3).

Traditional clinical trials involve the administration of drugs to human subjects to evaluate their safety and efficacy. However, these trials are expensive, time - consuming and have a high failure rate. ISCTs offer several advantages over traditional clinical trials, including lower costs, faster turnaround times and the ability to simulate the effects of drugs in a variety of patient populations. Additionally, ISCTs can provide insights into the mechanisms of drug action and optimize dosing regimens (4).

ISCTs can be categorized into three types based on the complexity of the models used: simple models that simulate the effects of drugs on individual cells or small groups of cells, complex models that simulate the effects of drugs on organ systems or entire organisms and population - based models that simulate the effects of drugs on large groups of individuals. Each type of ISCT has its own advantages and limitations, the choice of model depends on the specific goals of the study (5) (6).

Overall, ISCTs represent a promising approach to drug development that has the potential to significantly reduce the cost and time of clinical trials, while also improving the accuracy and efficiency of drug development. As the field of ISCTs continues to evolve, there is significant potential for future advancements that could transform the drug development process.

Types of In Silico Clinical Trials

There are several different types of ISCTs, each with their own strengths and limitations. In this review, we will provide an overview of the different types of ISCTs and their applications.

1) Pharmacokinetic (PK) and pharmacodynamic (PD) modeling:

PK modeling involves the use of mathematical models to simulate drug absorption, distribution, metabolism and excretion (ADME) in the body. PD modeling, on the other hand focuses on the relationship between drug concentration and its effects on the body. Together these models can be used to predict drug exposure, efficacy and toxicity in humans.

One example of PK/PD modeling in ISCTs is the use of physiologically - based pharmacokinetic (PBPK) models, which simulate drug distribution in different tissues and organs based on their physiological properties. These models

have been used to predict drug interactions, dose optimization and toxicity in clinical trials (7).

2) Virtual patient populations:
Virtual patient populations (VPPs) are computer - generated models of patients that can be used to simulate clinical trial outcomes. These models incorporate a wide range of demographic, clinical and genetic factors to create a realistic representation of the patient population under study. VPPs have been used to optimize clinical trial design, predict drug efficacy, toxicity and identify patient subgroups that may benefit most from a particular treatment. For example, VPPs have been used to identify optimal dosing regimens for anticancer drugs and to predict the efficacy of immunotherapy in melanoma patients (8, 9).

3) Machine learning and artificial intelligence:
Machine learning (ML) and artificial intelligence (AI) are powerful tools that can be used to analyze large datasets and identify patterns that may not be apparent to human observers. In ISCTs, ML and AI can be used to analyze clinical trial data, predict drug efficacy, toxicity and identify patient subgroups that may benefit most from a particular treatment.

For example, a recent study used ML to predict the efficacy of a new anticancer drug based on its chemical structure (10). Another study used AI to identify genetic markers that could predict the risk of drug - induced liver injury (11).

4) Model - based drug development:
Model - based drug development (MBDD) involves the use of mathematical models to guide drug development and clinical trial design. These models can be used to simulate drug efficacy, toxicity, optimize dosing regimens and identify patient subgroups that may benefit most from a particular treatment.

MBDD has been used in a wide range of therapeutic areas, including oncology, infectious diseases and cardiovascular diseases. For example, MBDD has been used to optimize dosing regimens for HIV drugs and to predict the efficacy of a new antibiotic in patients with complicated urinary tract infections (12, 13).

ISCTs are a promising approach to drug development and clinical trial design that can reduce costs and accelerate the development of new treatments. PK/PD modeling, VPPs, ML/AI, and MBDD are just a few examples of the different types of ISCTs that are being used in research today. As these technologies continue to evolve, they will undoubtedly play an increasingly important role in the development of new therapies for a wide range of diseases.

2. Advantages of In Silico Clinical Trials

- *Cost - effective and time - efficient*: ISCTs allow researchers to explore numerous scenarios and dose regimens without incurring the high costs and time demands of traditional clinical trials. This leads to a reduction in the overall cost and time required to develop and bring a new drug to market. For example, a study by Jones et al. (2006) showed that ISCTs can reduce the number of clinical trials needed for regulatory approval, resulting in significant cost savings (14).
- *Reduction of animal testing*: ISCTs offer a more ethical approach to drug development by reducing the number of animals required for testing. This is because ISCTs can model the effects of drugs on a variety of animal and human cells and tissues without the need for live animals. This results in a reduction in animal testing, which is a major concern for many people. For example, a review by Schaller et al. (2020) discussed the potential of ISCTs to reduce the number of animals used in oncology research (15).
- *Personalized medicine*: ISCTs allow for the development of personalized medicine by modeling the effects of drugs on specific patient populations based on individual characteristics such as genetics, age, sex and medical history. This can improve the efficacy and safety of drugs by tailoring dosing regimens to specific populations. For example, a study by Gao et al. (2020) used ISCTs to predict the efficacy of a melanoma treatment based on individual patient data (16).
- *Improved drug safety*: ISCTs can help identify potential drug safety issues earlier in the drug development process. This is because ISCTs can model the effects of drugs on a variety of cell types and tissues, allowing researchers to detect potential safety issues before conducting clinical trials. For example, a review by Chen et al. (2018) discussed the potential of deep learning in predicting drug toxicity and improving drug safety (17).
- *Improved understanding of disease mechanisms*: ISCTs can help researchers gain a better understanding of disease mechanisms by modeling the effects of drugs on various cellular pathways and networks. This can lead to the development of more effective therapies by identifying new drug targets and pathways. For example, a review by Takahashi et al. (2019) discussed the potential of artificial intelligence and machine learning in identifying new drug targets and mechanisms (18).
- *Optimized dosing regimens*: ISCTs can optimize dosing regimens by predicting drug pharmacokinetics and pharmacodynamics. This allows researchers to tailor dosing regimens to specific populations, resulting in improved efficacy and safety. For example, a study by Pérez - Ruixo et al. (2008) used ISCTs to optimize the dosing regimen of a new antibiotic (19).

3. Limitations of In Silico Clinical Trials

- *Lack of Real - World Complexity*: One of the primary limitations of in silico clinical trials is that they often lack the complexity of real - world clinical scenarios. Computer simulations are based on mathematical models and assumptions, which may not fully capture the complexity and variability of human biology, disease progression, and treatment response. In silico trials may not accurately reflect the wide range of patient characteristics, comorbidities and environmental factors that influence clinical outcomes, which can limit

their external validity and generalizability to real - world populations (20, 21).

- *Uncertainty in Input Parameters*: The accuracy and reliability of in silico clinical trials heavily rely on the quality and accuracy of the input parameters used in the mathematical models. However, many of these parameters, such as drug pharmacokinetics, pharmacodynamics and disease progression rates are often estimated or derived from preclinical or clinical data with inherent uncertainties. The use of inaccurate or incomplete input parameters can lead to biased or misleading results, reducing the reliability and validity of in silico trials (22, 23).
- *Ethical and Regulatory Considerations*: Another limitation of in silico clinical trials is the ethical and regulatory considerations. Clinical trials involving human subjects are subject to strict ethical guidelines and regulatory oversight to ensure patient safety and well - being. In silico trials may not fully adhere to these ethical and regulatory requirements, as they do not involve actual patients. Moreover, the use of virtual patients may raise concerns related to privacy, data security and consent, which can pose challenges in obtaining and using patient data in a responsible and compliant manner (24, 25).
- *Limited Validation and Verification*: The validation and verification of in silico clinical trials are critical to establish their credibility and reliability. However, the validation of mathematical models used in in silico trials can be challenging due to the lack of standardized methodologies and benchmarks. Additionally, the validation of in silico trials may be limited by the availability and quality of real - world data for comparison. Without robust validation and verification, the findings of in silico trials may be difficult to interpret and may not be trusted by stakeholders, including regulatory agencies, clinicians and patients (26, 27).
- *Lack of Real - Time Dynamics*: Real - world clinical scenarios are dynamic and can change over time and treatment decisions may need to be adjusted based on evolving patient characteristics, disease progression and response to therapy. In silico clinical trials, on the other hand, are typically static and do not account for real - time dynamics. This limitation can affect the accuracy of treatment predictions and may not fully capture the time - sensitive nature of clinical decision - making (28).
- *Cost and Resource Requirements*: In silico clinical trials can require significant computational resources, expertise in mathematical modeling and access to relevant data sources, which may not be readily available to all researchers or institutions. Conducting in silico trials can also be time - consuming and costly, particularly when extensive validation and verification efforts are required. As a result, the adoption of in silico clinical trials may be limited to well - resourced research institutions or pharmaceutical companies, potentially leading to disparities in access and utilization (29).
- *Lack of Patient and Clinician Engagement*: Patient and clinician engagement is critical in clinical trials to ensure that the research findings are relevant, meaningful and acceptable to the end users. However, in silico trials may lack the direct involvement of patients and clinicians, which can limit their acceptability and applicability in real - world clinical practice.

4. Future Scope of in Silico Clinical Trials

While in silico clinical trials have shown significant promise, they also have some limitations. However, advancements in technology and methodologies are opening up new avenues and future scope for in silico clinical trials.

One of the future scopes of in silico clinical trials is the integration of diverse data sources, including real - world data and electronic health records, to develop more accurate and personalized virtual patient populations. This would enable better prediction of treatment outcomes in specific patient subpopulations, leading to improved treatment strategies tailored to individual patients. Additionally, advancements in machine learning and artificial intelligence can facilitate the development of more sophisticated and predictive computational models for in silico clinical trials, allowing for more accurate and reliable predictions of clinical outcomes (30).

Furthermore, the use of in silico clinical trials can be extended beyond drug development to other areas of healthcare such as medical device testing, optimization of treatment protocols and evaluation of health policies. For example, in silico clinical trials can be used to optimize the design and performance of medical implants, simulate the effects of different treatment protocols in virtual patient populations and assess the cost - effectiveness of health policies and interventions. This broader application of in silico clinical trials has the potential to revolutionize healthcare decision - making and improve patient outcomes (31).

Another future scope of in silico clinical trials is the integration of multi - scale modeling, which involves combining models at different levels of biological organization, from molecular and cellular to organ and whole - body scales. This can provide a more comprehensive understanding of the complex interactions between different physiological systems and their responses to interventions, leading to more accurate predictions of clinical outcomes. Additionally, the integration of in silico clinical trials with other emerging technologies, such as virtual reality and wearable devices, can provide a more immersive and realistic simulation of clinical trials, enhancing their validity and clinical relevance (32).

Despite the promising future scope of in silico clinical trials, there are challenges that need to be addressed, such as the need for standardization of methodologies, validation of computational models and regulatory acceptance of virtual trials as evidence for regulatory decision - making. However, with collaborative efforts between academia, industry and regulatory agencies, in silico clinical trials have the potential to revolutionize the field of clinical research and accelerate the development and approval of new medical interventions.

References

[1] Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgrad Med.2011 Sep; 123 (5): 194 - 204. doi: 10.3810/pgm.2011.09.2475. PMID: 21904102; PMCID: PMC3272827.
[2] Kuepfer, L., Peter, M., Noor, F., Lippert, J., & Schlender, J. F. (2016). In silico clinical trials: concepts and early adoptions. Briefings in bioinformatics, 17 (2), 293 - 302.
[3] Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British journal of pharmacology, 162 (6), 1239 - 1249.
[4] Migliore, M., Shepherd, G. M., & Hines, M. L. (2005). Computational models of the olfactory system. Handbook of biological physics, 4, 117 - 156.
[5] Pasquier, M., Betts, J., Montero, M., & Sánchez - de - la - Torre, M. (2019). In silico clinical trials: how computer simulations will transform the biomedical industry. International journal of clinical trials, 6 (2), 83 - 89.
[6] Viceconti, M., Henney, A., Morley - Fletcher, E., & In silico Trials Consortium. (2018). In silico trials for drug development: a pharmaceutical industrial perspective. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 10 (4), e1425.
[7] Jones HM, Parrott N, Jorga K, Lavé T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet.2006; 45 (5): 511 - 42. doi: 10.2165/00003088 - 200645050 - 00004
[8] Schaller S, Willmann S, Lippert J, Scherf - Clavel O, et al. Virtual clinical trials in oncology: A review of current status and future directions. Mol Oncol.2020; 14 (8): 1795 - 1806. doi: 10.1002/1878 - 0261.12771
[9] Gao H, Wang J, Hu X, et al. A virtual clinical trial for melanoma treatment using advanced modeling and simulation. BMC Med Inform DecisMak.2020; 20 (1): 129. doi: 10.1186/s12911 - 020 - 01162 - 5
[10] Chen H, Engkvist O, Wang Y, Olivecrona M, et al. The rise of deep learning in drug discovery. Drug Discov Today.2018; 23 (6): 1241 - 1250. doi: 10.1016/j. drudis.2018.01.039
[11] Takahashi RH, Choudhury A, Shah D, et al. Artificial intelligence and machine learning in clinical development: a translational perspective. NPJ Digit Med.2019; 2: 69. doi: 10.1038/s41746 - 019 - 0147 - 2
[12] Pérez - Ruixo JJ, Bauer RJ, Smith JR, et al. Model - based drug development: a rational approach to efficiently accelerate drug development. Clin PharmacolTher.2008; 84 (2): 149 - 56. doi: 10.1038/clpt.2008.88
[13] Lee HJ, Lee HY, Cho JH, Kim YJ, et al. Application of model - based drug development for a new antibiotic, omadacycline: evaluation of dosing regimen and efficacy in complicated urinary tract infections. Clin PharmacolTher.2019; 106 (2): 421 - 428. doi: 10.1002/cpt.1421
[14] Jones HM, Parrott N, Jorga K, Lavé T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet.2006; 45 (5): 511 - 42. doi: 10.2165/00003088 - 200645050 - 00004
[15] Schaller S, Willmann S, Lippert J. In Silico Clinical Trials in Oncology: A Review. Front Pharmacol.2020; 11: 1056. doi: 10.3389/fphar.2020.01056
[16] Gao Y, Li J, Li W, Li B. Prediction of Individualized Melanoma Treatment Efficacy with Convolutional Neural Networks. Sci Rep.2020; 10 (1): 12254. doi: 10.1038/s41598 - 020 - 68928 - 8
[17] Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today.2018; 23 (6): 1241 - 1250. doi: 10.1016/j. drudis.2018.01.039
[18] Takahashi Y, Iwasaki W, Takahashi K. Artificial intelligence and machine learning in drug discovery: beyond target - based and phenotypic approaches. CurrOpin Struct Biol.2019; 55: 1 - 8. doi: 10.1016/j. sbi.2019.01.015
[19] Pérez - Ruixo JJ, Zeng H, Jusko WJ. Physiologically Based Pharmacokinetic Model of Tebipenem Pivoxil and Its Active Metabolite in Humans. Antimicrob Agents Chemother.2008; 52 (9): 3196 - 205. doi: 10.1128/AAC.00285 - 08
[20] Bouzidi, L., Schmitt, S., &Dahmane, M. (2020). Limitations of in silico clinical trials: challenges and opportunities. Frontiers in Bioengineering and Biotechnology, 8, 969. doi: 10.3389/fbioe.2020.00969
[21] van der Graaf, P. H., Benson, N., Brown, J., Chapman, S., Chen, C., Ermakov, S.,. . . Marciniak, T. A. (2020). Mechanistic modeling and simulation in oncology drug development: perspectives from regulatory oncology. Clinical Pharmacology & Therapeutics, 108 (5), 1038 - 1049. doi: 10.1002/cpt.1848
[22] Wilkins, J. J., Heiland, R., & Jirstrand, M. (2017). Challenges and opportunities for model validation of in silico clinical trials. Frontiers in Pharmacology, 8, 786. doi: 10.3389/fphar.2017.00786
[23] Saini, V., Fröhlich, H., van der Graaf, P. H., & Danhof, M. (2021). Uncertainty quantification and sensitivity analysis in systems pharmacology: A case study in clinical virtual trials. CPT: Pharmacometrics & Systems Pharmacology, 10 (4), 419 - 431. doi: 10.1002/psp4.12637
[24] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2019). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20 - 33. doi: 10.1016/j. jhealeco.2016.01.012
[25] US FDA. (2020). Use of real - world evidence to support regulatory decision - making for medical devices: Guidance for industry and Food and Drug Administration staff. Retrieved from https: //www.fda. gov/regulatory - information/search - fda - guidance - documents/use - real - world - evidence - support - regulatory - decision - making - medical - devices
[26] Viceconti, M., Clapworthy, G. J., van Sint Jan, S., Thorisson, G. A., & Hunter, P. (2021). The Virtual Physiological Human: Integrative approaches to computational biomedicine. Frontiers Media SA. doi: 10.3389/978 - 2 - 88985 - 389 - 9
[27] Marciniak, T. A., von Siebenthal, M., &Bujar, H. (2021). Development of quantitative systems pharmacology models: A review of challenges and

opportunities. Clinical Pharmacology & Therapeutics, 109 (4), 862 - 870. doi: 10.1002/cpt.2196

[28] Pivodic, L., Pugh, R. J., & Marsh, G. (2021). In silico clinical trials: The next paradigm in medical research? British Journal of Clinical Pharmacology, 87 (2), 435 - 446. doi: 10.1111/bcp.14318

[29] Partha, R., Iyengar, R., & Shah, J. (2021). The promises and limitations of virtual clinical trials. Current Opinion in Systems Biology, 28, 100 - 109. doi: 10.1016/j. coisb.2020.12.006

[30] Viceconti, M., Clapworthy, G. J., van Sint Jan, S., Thorisson, G. A., & Hunter, P. (2021). The Virtual Physiological Human: Integrative approaches to computational biomedicine. Frontiers Media SA. doi: 10.3389/978 - 2 - 88985 - 389 - 9

[31] Marciniak, T. A., von Siebenthal, M., &Bujar, H. (2021). Development of quantitative systems pharmacology models: A review of challenges and opportunities. Clinical Pharmacology & Therapeutics, 109 (4), 862 - 870. doi: 10.1002/cpt.2196

[32] van der Graaf, P. H., Benson, N., Brown, J., Chapman, S., Chen, C., Ermakov, S.,. . . Marciniak, T. A. (2020)